Nakata Bunzo, Sakimura Chie, Tendo Masashige, Yokomatsu Hideaki, Hori Takeshi
Surgery, Kashiwara Municipal Hospital, Kashiwara, JPN.
Surgery, Moriguchi Ikuno Memorial Hospital, Moriguchi, JPN.
Cureus. 2025 Jul 23;17(7):e88578. doi: 10.7759/cureus.88578. eCollection 2025 Jul.
The prognosis of triple-negative breast cancer (TNBC) with hepatic metastasis is generally poor. Here, we report the case of a 70-year-old woman with TNBC whose hepatic metastasis did not recur for more than three years after radiofrequency ablation (RFA). During this period, the patient received chemotherapies with relatively mild side effects, such as eribulin mesylate and gemcitabine, maintaining a good quality of life. Although PARP inhibitors and immune checkpoint inhibitors are now available for TNBC, many cases are not eligible for these treatments due to the absence of specific target molecules. RFA may be a useful option in selected cases of hepatic metastasis from TNBC.
三阴性乳腺癌（TNBC）发生肝转移后的预后通常较差。在此，我们报告一例70岁的TNBC女性患者，其肝转移灶在接受射频消融（RFA）治疗后三年多未复发。在此期间，患者接受了副作用相对较轻的化疗，如甲磺酸艾瑞布林和吉西他滨，维持了良好的生活质量。尽管目前PARP抑制剂和免疫检查点抑制剂可用于TNBC治疗，但由于缺乏特定的靶分子，许多病例不符合这些治疗条件。对于TNBC肝转移的某些特定病例，RFA可能是一种有用的选择。
